Interestingly, the glucose-lowering drug rosiglitazone (RGZ), a thiazolidinedione ligand of the peroxisome proliferator-activated receptor gamma (PPARγ), previously shown to affect ACC tumor growth and invasiveness in preclinical studies [9,10,11,12], has more recently proven to exert its anti-cancer activity by interfering with the CXCL12/CXCR4 axis in colon and prostate cancer cells [13,14]. Here, CXCR4 is linked to neoplasm.